The Cleveland Clinic Center for Continuing Education
Speaker Disclosure
48th Annual Macula Society Meeting
02/12/2025
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias. All relevant financial relationships have been mitigated.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
|
K.Bailey Freund, MD |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Michael Ip, MD |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Anat Loewenstein, MD |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Srinivas Sadda, MD |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
David Sarraf, MD |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Seung-Young Yu, MD |
|
The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Anita Agarwal, MD
Gaetano Barile, MD
Daniel Martin, MD
Lawrence J. Singerman, MD
Macula Disclosures for 2025 - PRESENTERS
Case Conference I
A case of vitreous haze
Milman, Tatyana
- Nothing to Disclose
The Eyes are Windows to the Soul
Chowers, Itay
Orsight Pharma - Consulting
Remepy - Consulting
Occutrack - Consulting
Million Dollar Diagnosis
Gross, Jeffrey
BioGenware - IP Rights, Private
Coherus - Consulting
"Sir, You are a Basket Case!"
Daniels, Anthony
Aura Biosciences - Employment
Acrotech Biopharma - Research
Sudden onset of bilateral symmetric multiple serous macular detachments
Goldstein, Michaella
Bayer - Consulting, Speaking, Research
Roche - Speaking, Research
Abbvie - Speaking
novonordisk - Consulting, Research
Double Jeopardy
Kim, Min
- Nothing to Disclose
More than Meets the Eye
McCannel, Colin
DORC - Consulting
Unusual case of recurrent pancreatitis
Barr, Charles
- Nothing to Disclose
Case Conference II
Double Trouble- Or Is It?
Bhende, Muna
- Nothing to Disclose
Not Just A Cotton Wool Spot!
Kim, Benjamin
Lexitas / Clearside - Consulting
Synergy Research - Consulting
Genentech - Consulting
Asclepix Therapeutics - Consulting
Teenage cavities
Robson, Anthony
- Nothing to Disclose
Maculopathy
Agarwal, Anita
- Nothing to Disclose
Retinal Vasoproliferative Lesion with Traction Detachment
Barile, Gaetano
- Nothing to Disclose
Treatments of popcorn-like abnormal blood vessels associated with myopic macula paravascular retinoschisis
Yu, Weihong
- Nothing to Disclose
Dynamics of the blood under ILM
Rodriguez, Francisco
Bayer - Consulting, Speaking
Roche - Consulting, Speaking
Janssen - Consulting
Iveric Bio - Consulting
Prioritizing Variants of Unknown Significance in Retinitis Pigmentosa Using Clinical Electrophysiology
Tsang, Stephen
- Nothing to Disclose
Mystery Case: What's missing in this image?
Jung, Jesse
Carl Zeiss Meditec - Consulting
Iveric Bio/Astellis - Consulting
Genentech - Consulting
Regeneron - Consulting
AMD: Epidemiology
The Prevalence of Visual Impairment in Elderly Population in Retirement Home Care and Home Based Care (Spitex) in Switzerland (POVIE-Study)
Zweifel, Sandrine
Alcon - Consulting
Allergan - Consulting
Apellis - Consulting
Bayer - Consulting, Research
Endogena - Consulting
Novartis - Consulting, Research
Roche - Consulting, Research
Zweiss - Consulting
Infocus Clinical Research - Consulting
The Power of Electronic Medical Records in Age-Related Macular Degeneration
Levy, Jaime
- Nothing to Disclose
Black and Hispanic patients with Age-related Macular Degeneration and Subretinal Drusenoid Deposits
Smith, R
Roche Pharmaceuticals - Consulting
Roche Pharmaceuticals - Consulting
Statins and genetics in the risk of progression of age-related macular degeneration
Silva, Rufino
Bayer, - Consulting, Advisor
Roche - Consulting, Advisor
THEA - Advisor
THEA - Advisor
Astellas - Advisor
¬Propensity Matched Analysis of the Risk of Age-Related Macular Degeneration with Systemic Immune-Mediated Inflammatory Disease
Talcott, Katherine
Alimera - Consulting
Abbvie - Consulting
Apellis - Consulting
Astellas - Speaking
Bausch and Lomb - Consulting
Eyepoint - Consulting
Genentech - Consulting, Speaking
Outlook Therapeutics - Consulting
Regeneron - Consulting, Research
Zeiss - Consulting, Speaking, Research
DIABETIC RETINOPATHY I: TRIALS
Baseline Characteristics and Outcomes of Patients Treated with Aflibercept 8 mg at Shortened, Maintained, or Extended Dosing Intervals Through 96 Weeks in PHOTON
Hariprasad, Seenu
AbbVie - Consulting, Speaking
Allergan - Consulting, Speaking
Alimera Sciences - Consulting, Speaking
Bayer - Consulting, Speaking
Biogen - Consulting, Speaking
Coherus - Consulting, Speaking
Harrow - Consulting, Speaking
Iveric Bio - Consulting, Speaking
Regeneron Pharmaceuticals, Inc. - Consulting, Speaking
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Brown, David
Regeneron Pharmaceuticals, Inc - Advisor
Bayer - Advisor
Genentech/Roche - Advisor
Intraocular Pressure Outcomes With Aflibercept 8 mg and 2 mg in Patients With Diabetic Macular Edema Through Week 96 of the Phase 2/3 PHOTON Trial
Grewal, Dilraj
Apellis - Consulting
Regeneron - Consulting
Zeiss - Consulting
Astellas - Consulting
Roche - Consulting
Priovant - Research
Genentech - Research
Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Scott, Adrienne
Alimera - Consulting
Allergan/AbbVie - Consulting
Bausch + Lomb - Consulting
Dutch Ophthalmic Research Center - Consulting
EyePoint - Consulting
Iveric Bio - Consulting
Regeneron - Consulting
Genentech, Inc./Roche - Consulting, Research
Four-Year Outcomes of Faricimab in DME: Safety and Efficacy Results From the RHONE-X Long-Term Extension Trial
Khanani, Arshad
4D Molecular Therapeutics - Consulting, Research
AbbVie - Consulting
Adverum - Consulting, Research
Alcon - Consulting
Amgen - Consulting
Annexin - Consulting
Annexon - Consulting, Research
Apellis - Consulting, Research
Aviceda - Stock Options, Consulting, Research
Beacon Therapeutics - Consulting
Boehringer Ingelheim - Consulting
Clearside - Consulting
Complement Therapeutics - Consulting
Exegenesis Bio - Consulting, Research
EyePoint - Consulting, Research
Frontera - Consulting
Genentech, Inc. - Consulting, Research
Gyroscope - Consulting, Research
iLumen - Consulting
Iveric Bio - Consulting, Research
Janssen - Consulting, Research
Kodiak Sciences - Consulting, Research
Kriya - Consulting
Nanoscope - Consulting
Novartis - Consulting
Ocular Therapeutix - Consulting, Research
Oculis - Stock Options, Consulting, Exec Board
Ocuphire - Consulting
OcuTerra - Consulting
Olives Bio - Consulting
Opthea - Stock Options, Consulting
Oxular - Consulting, Research
Oxurion - Consulting
Perfuse - Stock Options, Consulting
Ray Therapeutics - Consulting
RecensMedical - Stock Options, Consulting
Regeneron - Consulting
Regenxbio - Consulting, Research
Revive - Consulting
RevOpsis - Stock Options, Consulting
Roche - Consulting
Sanofi - Consulting
Stealth - Consulting
Thea - Consulting
Unity - Consulting
Vanotech - Consulting
Vial - Stock Options, Consulting
Alexion - Research
Neurotech - Research
Polyphotonix - Stock Options
Greater Reduction in Hard Exudates With Faricimab vs Aflibercept in Patients With DME: Biomarker Results From the Phase 3 YOSEMITE/RHINE Trials
Elman, Michael
Alexion Pharmaceuticals Inc - Research
Axon Clinical Research - Research
Fortrea Inc - Research
Jaeb Center for Health Research (JCHR) - Research
KCRN Research - Research
Neumora Therapeutics, Inc - Research
Notal Vision - Research
The Lowy Medical Research Institute - Research
Xenon Pharmaceuticals, Inc; - Research
Notal Vision - Other
IMAGING I AND MACULAR DISEASE
North Carolina Macular Dystrophy, Haplotype analysis of 37 families shows single founders for each mutation
Small, Kent
- Nothing to Disclose
Pathogenic Mechanisms of Immune Checkpoint Inhibitor (ICI)-Associated Choroidal and Retinal Adverse Reactions
Johnson, Mark
Aura Biosciences - Contractor
Opthea - Contractor
Progression of atrophy associated with myopic neovascular maculopathy
Couturier, Aude
- Nothing to Disclose
Prevalence, Features, and Outcomes of Type 1 Neovascularization in Eyes with Angioid Streaks
Bandello, Francesco
- Nothing to Disclose
Anti-VEGF Therapy for Proliferative Sickle Cell Retinopathy
Lim, Jennifer
Genentech/ Roche - Consulting, Research
Regeneron - Consulting, Research
Opthea - Consulting
AbbVie / Astellas - Consulting, Research
Aura Bioscience - Consulting
Alimera - Advisor
Bausch & Lomb - Advisor
Cognition - Consulting
Eyepoint - Consulting
Janssen/ Johnson & Johnson - Consulting, Research
Luxa - Consulting
NGM - Research
Genentech - Research
Ocular Therapeutix - Consulting, Research
Regeneron - Research
RegenexBio - Research
Spring Vision - Research
Unity - Consulting
Viridian - Consulting
Stealth - Research
Kyoto Drug Discovery - Research
Graybug - Research
Aldeyra - Research
Ocular Therapeutix - Research
Use of a novel individualized, clustered at-home virtual reality perimetry test to measure retinal sensitivity in patients with Geographic Atrophy (GA)
Csaky, Karl
Abbvie - Consulting
Adverum Biotechnologies - Other
Annexon Biosciences - Consulting
Cognition Therapeutics - Consulting
EyeBio - Consulting
F. Hoffman-La Roche AG - Consulting
Genentech, Inc. - Consulting
Astellas - Consulting
Johnson & Johnson Health Care Systems Inc. - Consulting
Merck - Consulting
NGM Biopharmaceuticals - Consulting
Novartis - Consulting
Regeneron Pharmaceuticals, Inc. - Consulting
Boehringer Ingelheim Pharmaceuticals - Consulting
Vivid Vision, Inc, of San Francisco, CA - Employment
TUMORS
Comparison of Genetic Profile and Metastatic Outcomes of High Risk Nevi Undergoing Observation Versus Immediately Treated Uveal Melanoma
Schefler, Amy
Castle Biosciences - Research
Aura Biosciences - Research
Regeneron - Consulting
Genentech - Research
Ideaya Biosciences - Consulting
Small Choroidal Melanoma: Paradigm shift to early treatment combined with FNAB
Murray, Timothy
Alcon - Consulting
High-Dose Intravitreal Topotecan for Recurrent Retinoblastoma, Subretinal Seeds, and Vitreous Seeds in 13 Consecutive Cases
Shields, Carol
- Nothing to Disclose
Blood-Derived Cell Free DNA in the Diagnosis of Solitary Amelanotic Choroidal Lesions
Francis, Jasmine
- Nothing to Disclose
INHERITED RETINAL DYSTROPHY I: TRIALS
Phase I Study of Intravitreal Injection of Autologous CD34+ Stem Cells from Bone Marrow in Eyes with Vision Loss from Retinitis Pigmentosa
Park, Susanna
- Nothing to Disclose
Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa:126-Week Topline Results from the REMAIN Follow-Up Study (REMAIN)
Gonzalez, Victor
ORA/4D - Research
60° PHARMACEUTICALS - Research
Abbvie - Consulting
AG (ADULTS) - Research
AIVIVA - Research
ALCON/NOVARTIS - Consulting, Research
-
Allergan - Consulting, Research
ALLGENESIS - Research
ALNYLAM PHARMACEUTICALS - Research
ANNEXIN - Research
GALE - Research
ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE - Consulting, Research
BAUSCH AND LOMB - Consulting
BEAVER-VISITEC INTERNATIONAL, INC - Consulting
BOEHRINGER INGELHEIM - Research
CHENGDU KANGHONG BIOTECHNOLOGY CO., LTD. - Research
CONDOR - Research
CUDMEP2 - Research
ENDOGENA - Research
ENVISION UBX - Research
GENENTECH - Consulting, Research
GRAYBUG VISION, INC. - Research
ICONIC THERAPEUTICS - Research
INSITE - Research
IONIS - Research
JOHNSON & JOHNSON SURGICAL VISION - Research
LEOPARD - Research
IQVIA - Research
Adverum - Research
MALLINCKRODT ARD INC. - Research
Alluvium - Research
-
-
OcuTerra Therapeutics - Research
ONL Therapeutics, Inc - Research
OPTHEA LTD. - Research
Oxular Limited - Research
EyeBio EYE103-101 - Research
REGENERON - Consulting, Research
Rezolute, Inc. - Research
RIBOMIC USA INC. - Research
RXSIGHT, INC. - Research
SANTEN PHARMACEUTICAL - Consulting, Research
SYNCHRONICITY/YUTIQ - Research
THROMBOGENICS INC SUBSIDIARY OXURION - Consulting, Research
TOPCON - Consulting
VALEANT - Consulting, Research
VISTA - Research
Crimson - Research
ReNEW - Research
TED - Research
Avonelle-X - Research
CONCERTO - Research
DAVIO2 EYP-1901 - Research
Lightsite III - Research
Oculis Diamond (Stage 1) - Research
Oculis Diamond (Stage 2) - Research
Voyage - Research
Rhone-X - Research
4DMT - Research
American Genomics, LLC (ADULTS) - Research
ALIMERA - Stock
Panoptica - Stock
Eclipse Sciences - Stock
Nanoscope Therapeutics (Remain, Restore, Starlight, Observational) - Stock
Apellis Gale - Research
Curacle Co., Ltd. - Research
Ocuphire Pharma Inc. - Consulting, Research
Aviceda Therapeutics, Inc. - Stock, Research
SPIAM-301 - Research
IMVT 1401-3201 - Research
Ocu410-101 - Research
KLRS-100 - Research
Updated Safety Results from the PIONEER study : Optogenetics for Non-Syndromic Retinitis Pigmentosa
Sahel, Jose
- Nothing to Disclose
PRODYGY: A first-in-human trial of rod-derived cone viability factor (RdCVF) gene therapy in subjects with rod-cone dystrophy
Audo, Isabelle
Janssen, Sepubio - Consulting
-
Interim Safety and Efficacy of ATSN-201 Dose Escalation Study in Patients with X-linked Retinoschisis (XLRS)
Kay, Christine
Atsena Therapeutics - Consulting
4 D Molecular Therapeutics - Research
Nanoscope - Consulting
Foundation Fighting Blindness - Research
Beacon Therapeutics - Research
Kiora - Consulting
Adverum - Consulting
Sanofi - Research
Regenx Bio - Research
Gyroscope - Research
Janssen - Research
Meira GtX - Research
Safety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy(BCD)
Li, XiaoXin
-
NGGT (Suzhou) Biotechnology Co., Ltd, China. - Research
Oral Gildeuretinol Slows Progression of Stargardt Disease: Safety and Efficacy Results from The TEASE Program
Ferrone, Philip
- Consulting, Employment
Abbvie/Allergan - Consulting
Alcon - Consulting
Apellis - Consulting, Research, Employment
Aviceda - Consulting, Research
Annexon - Consulting
Cognition - Consulting
Genentech - Consulting, Research
Neurotech - Consulting
Opthea - Consulting
Regeneron - Consulting
Alkeus Pharmaceuticals, Inc. - Research
Belite Bio - Research
EyePoint - Research
Regeneron - Research
Outlook - Research
RegenexBio - Research
Rezolute - Research
NON-NV AMD I: TRIALS
Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration: Evaluation of OCU410 Safety and Efficacy from Phase 1/2 ArMaDa Study Results
Chhablani, Jay
Allergan; Novartis; Salutaris; OD-OS; Erasca; B&L, Iveric Bio; Eyepoint - Consulting
Ocugen - Research
Inflammasome Inhibition with Kamuvudine K8: A Prospective Clinical Trial in Bilateral Geographic Atrophy (GA)
Ambati, Jayakrishna
Inflammasome Therapeutics - IP Rights
Abbvie - Consulting
Retinal Solutions - Consulting
Saksin LifeSciences - Consulting
-
AVD-104 for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Review of the Phase 2a SIGLEC Findings and an Overview of the SIGLEC Phase 2b Study
Avery, Robert
4DMT - Consulting
Alcon - Stock, Consulting
Alimera - Consulting
Allergan - Consulting
Amgen - Consulting
Abbvie - Stock, Consulting
Adverum - Stock
Alderya - Stock
Apellis - Stock, Consulting
Asclepix - Consulting
Aviceda - Stock Options, Consulting
Bausch + Lomb - Consulting
Astrazeneca - Stock
Cardinal Health - Consulting
Clearside - Consulting
Coherus - Consulting
Eyepoint Pharma - Stock, Consulting
Forwardvue - Stock Options, Consulting
Genentech - Consulting, Speaking
Glaukos - Stock, Consulting
Imprimis - Consulting
Ingenia - Stock Options, Consulting
Iveric - Stock
Astellas - Consulting
Kodiak - Stock
Kriya - Consulting
KYS Vision - Stock Options
Merit - Consulting
Nanoscope - Consulting
Novartis - Stock, Consulting
Nvasc - Stock Options
Ocular Therapeutix - Stock, Consulting
Ocuterra - Consulting
Outlook - Stock, Consulting
Oyster Point Pharma - Stock
Pixium - Consulting
Pr3vent AI - Consulting
PulseMedica - Consulting
RegenXbio - Consulting, Research
Regeneron - Stock
Replenish - Stock
ReVana Therapeutics - Stock, Exec Board
Santen - Consulting
Tenpoint Therapeuti - Consulting
Verana Health - Stock Options
Vial - Consulting
Impact of C1q Inhibition on Visual Acuity Protection and Central Subdomain Anatomical Preservation with ANX007 in the Phase 2 ARCHER Trial
Khurana, Rahul
AbbVie - Consulting
Clearside - Consulting, Research
Annexion - Research
Apellis - Research
Genentech/Roche - Consulting, Research
Regeneron - Consulting
RegenXBio - Consulting, Research
Ophthea - Research
C1q Inhibition Attenuates Microglia-Induced Neuronal Injury: Implications for GA and Neurodegenerative Diseases
Lad, Eleonora
Lutronic Vision, Nanoscope Therapeutics, NGM Biopharmaceuticals, Novartis, Ocular Therapeutics, OD-OS, Osanni Bio, Perceive Bio, Pulse Sight Therapeutics, Regeneron, Retrotope, Roche, Sanofi, SepulBio, Sitala Bio, Thea Laboratoires - Consulting
4-DMT, Alexion, Allegro, Alkeus, Alnylam, Apellis, Aspen Neuroscience, Aviceda, BioCryst, Blue Rock, Boehringer Ingelheim, Broadwing Bio, Complement Therapeutics, Emmecell, Galimedix, IVERIC Bio/Astellas, Janssen, Kriya Therapeutics, LumiThera - Consulting
Alexion, Apellis, Belite Bio, Boehringer Ingelheim, Gemini Therapeutics, IVERIC Bio, Janssen, LumiThera, Neurotech, NGM Biopharmaceuticals, Novartis, Roche. - Research
Osannibio - Stock
Annexon Biosciences - Consulting
Oral Gildeuretinol in Geographic Atrophy Secondary to AMD: Safety and Efficacy from SAGA, a 2-Year, Randomized, Double-Masked, Placebo-Controlled Study
Suner, Ivan
- Consulting, Speaking, Research
Alimera - Consulting, Research
Apellis - Consulting, Speaking, Research
Genentech/Roche - Consulting, Speaking, Research
Iveric Bio/Astellas - Consulting
Aura Bioscience - Research
Regeneron - Consulting, Research
Alkeus Pharmaceuticals - Research
EyePoint - Consulting, Research
Ocular Therapeutix - Consulting, Research
One-year results of photobiomodulation for dry intermediate AMD: a single-center retrospective study
Cohen, Salomon
Abbvie, Bayer, Novartis, Roche, Thea - Consulting
24-month Evaluation of Anatomical Effects of Photobiomodulation with the Valeda® Multiwavelength Light Delivery System in Dry Age-Related Macular Degeneration
Jaffe, Glenn
Annexon - Consulting
4D-MT - Consulting
Regeneron - Consulting
Kriya - Consulting
Astellis - Consulting
Roche/Genentech - Consulting
Neurotech - Consulting
Eyepoint - Consulting
Ocular Therapeutix - Consulting
Boehringer Ingelheim - Consulting
IMAGING II: DIABETIC RETINOPATHY
Refining Diabetic Retinopathy Severity Assessment: A Comparative Analysis of Ultrawide Field Fluorescein Angiography and Color Fundus Photography
Silva, Paolo
- Research
Optos plc - Research
Kubota Vision - Research
AEye Health - Research
Imaging Biomarkers as Predictors of Response to Treat-and-Extend Treatment in Diabetic Macular Edema
Kim, Kiyoung
- Nothing to Disclose
Impact of Early Intraretinal Fluid (IRF) Reduction on Outcomes in DME
Chan, Clement
Bayer Healthcare Pharmaceuticals - Other
Genentech - Other
Iveric Bio - Other
Juvenile Diabetic Research Foundation - Other
National Eye Institute - Other
NIDDK - Other
Opthea - Other
Retinal Patch Technologies, Inc - Other
Unifeye Vision Partners - Stock
Retinal Microglial Activation Status in Diabetic Retinopathy assessed over time by Volumetric Adaptive Optics OCT
Pollreisz, Andreas
Bayer - Consulting
Roche - Consulting, Research
Abbvie - Consulting
Oertli Instruments - Consulting
Zeiss Meditec - Research
Retinal sensitivity and retinal ischemia in diabetic retinopathy (DR): A prospective, observational, longitudinal cohort study.
Lois, Noemi
THIS IS NOT APPLICABLE - I HAVE NO RELATIONSHIP WITH ANY INELIGIBLE COMPANY. -
Correlation of Perfusion Deficits in the Macular and Peripapillary Areas versus Retinal Mid-periphery in Diabetic Retinopathy: a Wide-field OCT Angiography Study
Midena, Edoardo
- Nothing to Disclose
IMAGING III: INNOVATIONS AND NEW APPLICATIONS
Assessment of the Metabolic Function of Retinal Pigment epithelial Cells in the Living Human Eye
Sadda, SriniVas
Amgen - Consulting
Alnylam - Consulting
Allergan/Abbvie - Consulting
Apellis - Consulting
Astellas/Ivericbio -
Astellas/Ivericbio - Consulting
Biogen - Consulting
Samsung Bioepis - Consulting
Boerhinger Ingelheim - Consulting
Neurotech - Consulting
ONL Tx - Consulting
Nanoscope - Consulting
Jannsen - Consulting
Roche - Consulting, Speaking
Novartis - Consulting, Speaking
Regeneron - Consulting
Bayer - Consulting
Oxurion - Consulting
Splicebio - Consulting
Heidelberg - Consulting
Nidek - Speaking
Topcon - Speaking, Research
Optos - Consulting, Speaking, Research
Carl Zeiss Meditec - Research
NotalVision - Consulting
iCare - Consulting
Ikerian - Consulting
CharacterBio - Consulting
Novel whorl-like collagen fiber arrangement around emissary canals in the posterior sclera
Ohno-Matsui, Kyoko
TOMEY - Employment
Ocular Blood Velocity Measurement with Optical Coherence Tomography
Spaide, Richard
Topcon Healthcare - Consulting
Regeneron - Consulting
- Consulting
Genentech - Consulting
Heidelberg Engineering - Consulting
Alcon - Consulting
Roche -
Janssen - Consulting
A Flicker in the Light - Intermittent Choriocapillaris Perfusion in Sickle Cell Disease
Rosen, Richard
Optovue - Stock Options, IP Rights, Consulting, Research
Boehringer-Ingelheim - Consulting
Lumithera - Consulting, Research, Advisor
Kyoto DD - Consulting, Research, Other
CellView - Stock Options, Consulting, Research
Opticology - Stock
Guardion Health - Stock
Topcon - Research
Topcon - Research
Intalight - Research
Ocusciences - Research
Canon - Research
Topographic Measurement of the Subretinal Pigment Epithelium Space in Normal Aging and Intermediate Age-Related Macular Degeneration Using High-Resolution OCT
Waheed, Nadia
Nidek, Topcon, Olix Pharmaceuticals, Aavantgarde Bio, Samsung Bioepis, Alkeus Pharmaceuticals - Consulting
Zeiss, Topcon, Nidek - Research
Ocular Therapeutix - Employment
-
Ocudyne, Valitor, Beacon Therapeutics, Iolyx - Stock Options
NON-NV AMD II: FUNCTION VS STRUCTURE
Genetic Associations of Delayed Rod-Mediated Dark Adaptation and Other Visual Functions at the Aging-AMD Interface Implicate Microvascular Involvement
Curcio, Christine
Genentech/ Roche - Consulting
Pitfalls in Measuring Reading Speed in Patients with Geographic Atrophy and Good Visual Acuity
Sunness, Janet
- Nothing to Disclose
Effect of Intravitreal AVD-104 on Junctional Hyperautofluorescence and Outer Retinal Layer Thickness in Eyes with Geographic Atrophy
Ip, Michael
Adverum, Alimera, Allergan, Amgen, Apellis, Astellas, Clearside Biomedical, Genentech, Novartis, Regeneron, Regenxbio - Consulting
Adverum, Apellis, Astellas, Biogen, Genentech, Lineage Cell Therapeutics, ONL Therapeutics, Regeneron, Regenxbio, Splice Bio, 4DMT - Research
Baseline Quantitative Ellipsoid Zone (EZ) Integrity Parameters in ReCLAIM-2: Impact on Photoreceptor Loss and Low Luminance BCVA in Dry AMD
Ehlers, Justis
Allegro, Zeiss, Alcon, Allergan, Regeneron, Adverum Biotechnologies, REGENXBIO, ThromboGenics/Oxurion, Astellas, Apellis, Ophthalytics, Beyeonics, Roche, Novartis, Boehringer Ingelheim, Iveric Bio/Astellas - Consulting
Regeneron, Boehringer Ingelheim, Genentech, Roche, Novartis, Alcon, Adverum, Iveric Bio, and Allergan - Research
Stealth Biotherapeutics - Consulting, Research
Assessment of local Sensitivity Loss in iRORA and cRORA lesions in intermediate Age-related Macular Degeneration (iAMD) by high-resolution Microperimetry
Holz, Frank
Zeiss - Consulting, Research
Apellis - Consulting, Research
astellas - Consulting, Research
Bayer - Consulting, Research
Novartis - Consulting, Research
Roche - Consulting, Research
Janssen - Consulting, Research
Abbvie - Consulting, Research
Alexion - Consulting
Alzehon - Consulting
4DMT - Consulting
Stealth - Consulting
Heidelberg Engineering - Consulting, Speaking, Research
Oxurion - Consulting
Science/Pixium - Consulting, Research
Retinal Sensitivity After 36 Months of Pegcetacoplan Treatment for Geographic Atrophy in the GALE Study
Kim, Judy
AbbVie - Consulting
Apellis - Consulting
Allergan - Consulting
Bausch & Lomb - Consulting
Alcon - Consulting
Clearside Biomedical - Consulting
Eyepoint - Consulting
Genentech/Roche - Consulting
Neurotech - Consulting
Notal Vision - Consulting
Outlook Therapeutics - Consulting
Regeneron - Consulting
BASIC SCIENCE I
Unraveling Cone Photoreceptor Metabolic Dependencies to Identify Novel Neuroprotective Strategies
Wubben, Thomas
Insmed - Consulting
Understanding the retinal recovery response to injury
Ufret-Vincenty, Rafael
- Nothing to Disclose
Photoreceptor Anastasis: Recovery from the Brink of Death
Zacks, David
ONL Therapeutics, Inc. - Stock
Retinal perivascular macrophages regulate immune cell infiltration during neuroinflammation
Lavine, Jeremy
Genentech - Consulting
Therini Bio - Research
Line 6 Biotechnology - Consulting
Cross-species single-cell analysis reveals factors limiting human retinal neuron regeneration
Hafler, Brian
Roche - Research
DIABETIC RETINOPATHY II: TRIALS
Evaluating OTX-TKI in Non-Proliferative Diabetic Retinopathy: Results from the Phase 1 HELIOS Trial
Dhoot, Dilsher
Alcon Pharmaceuticals - Consulting
Alimera Sciences, Inc. - Consulting
Allergan - Consulting
Annexon - Consulting
Apellis Pharmaceuticals, Inc. - Consulting
Bayer Healthcare Pharmaceuticals, Inc. - Consulting
Biocryst - Consulting
Coherus - Consulting
EyePoint Pharmaceuticals - Consulting
Genentech - Consulting
IvericBio - Consulting
Novartis - Consulting
Ocular Therapeutix, Inc. - Consulting, Research
Optos, Inc. - Consulting
Outlook Therapeutics - Consulting
Oxular - Consulting
Regeneron - Consulting
REGENXBIO - Consulting
Roche - Consulting
Santen, Inc. - Consulting
CRIMSON, a Phase IIb Randomized Controlled Trial of BI 764524 in Patients With Non‑Proliferative Diabetic Retinopathy: Rationale, Study Design, and Protocol
Vujosevic, Stela
Abbvie - Consulting, Speaking
Alimera - Consulting, Speaking
Apellis - Consulting
Bayer - Consulting
Boehringer Ingelheim - Consulting, Speaking
Novartis - Consulting
RetinAI - Consulting
Roche - Consulting, Speaking
Zeiss - Consulting
Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE® Study
Marcus, Dennis
4D Molecular Therapeutics - Consulting
Annexon - Consulting
Apellis - Consulting
Clearside - Consulting
Coherus - Consulting
Genentech/Roche - Consulting
REGENXBIO - Consulting
Regeneron - Consulting
Vial - Consulting
Ocular Therapeutics - Consulting
Vantage Biosciences - Consulting
Alexion Pharmaceuticals - Research
Annexon - Research
Apellis Pharmaceuticals - Research
Aviceda therapeutics - Research
Carnegen Co LTD - Research
Clearside Biomedical - Research
Genentech/Roche - Research
Gyroscope Therapeutics - Research
Hoffman Roche - Research
Ionis Pharmaceuticals - Research
Iveric Bio - Research
Kodiak Sciences - Research
Kyowa Kirin - Research
National Eye institute - Research
Oculis - Research
Ocular Therapeutics - Research
Opthea Ltd - Research
REGENXBIO - Research
Rezolute Biotech - Research
Shanghai Hengenix Bio - Research
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide
Barkmeier, Andrew
- Nothing to Disclose
Global Real-World Clinical and Anatomical Outcomes With Faricimab in Treatment-Naïve Patients With nAMD or DME From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
Schmitz-Valckenberg, Steffen
AlphaRet - Consulting
Apellis - Consulting
Bioeq - Consulting
eyeDNA - Consulting
Galimedix - Consulting
Katairo - Consulting
LaScience - Consulting
Novartis - Consulting, Other
Perceive Therapeutics - Consulting
Roche - Consulting, Other
SparingVision - Consulting
STZ GRADE Reading Center - Other
Bayer - Other
Heidelberg Engineering - Other
Zeiss - Other
Treatment Patterns, Visual Outcomes, and Safety in Eyes With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab in the UK: 1-Year Results From the Faricimab Real-World Evidence (FARWIDE) Study
Sivaprasad, Sobha
AbbVie - Consulting, Research
Amgen - Consulting, Research
Apellis - Consulting, Research
Bayer - Consulting, Research
Biogen - Consulting, Research
Boehringer Ingelheim - Consulting, Research
Novartis - Consulting, Research
EyeBio - Consulting, Research
EyePoint - Consulting, Research
Janssen - Consulting, Research
Kriya - Consulting, Research
Novo Nordisk - Consulting, Research
Ocular Therapeutix - Consulting, Research
OcuTerra - Consulting, Research
Optos - Consulting, Research
Roche - Consulting, Research
Sanofi - Consulting, Research
Stealth - Consulting, Research
Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab in the US: The FARETINA Study
Borkar, Durga
Alimera - Consulting
Apellis - Consulting
AbbVie/Allergan - Consulting
Astellas - Consulting
Genentech - Consulting
Glaukos - Consulting
ONL Therapeutics - Consulting
Regeneron - Consulting
NEOVASCULAR AMD I: TRIALS
Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Interim Results of Bilateral Dosing from a Fellow Eye Study
Garg, Sunir
Allergan, American Academy of Ophthalmology, Apellis, Bausch + Lomb, Boehringer Ingelheim, Coherus, Johnson & Johnson, Merck Manuals, Regeneron, Zeiss - Consulting
American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, Kodiak, NGM Bio, Regeneron - Research
Subretinal LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Two-year Results of The First-In-Human Study and Preliminary Results of The Phase I Study
SUN, XIAODONG
Kanghong - Consulting
Bayer - Consulting
Roche - Consulting
Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response
Boyer, David
4D Molecular Therapeutics (4DMT) - Consulting
AbbVie Inc. - Consulting
Adverum Biotechnologies - Consulting
AiViva Biopharma - Consulting
Alcon - Consulting
Aldeyra Therapeutics - Consulting
Alimera Sciences - Consulting
Alkahest - Consulting
Allegro - Consulting
Allergan - Consulting
Allgenesis - Consulting
Alumis - Consulting
Amgen - Consulting
Annexon Biosciences - Consulting
Apellis Pharmaceuticals - Consulting
Applied Genetec Technologies Corp (AGTC) - Consulting
AsclepiX Therapeutics - Consulting
Ashvattha Therapeutics - Consulting
Aviceda Therapeutics - Consulting
Bausch & Lomb - Consulting
Bayer - Consulting
Belite Bio - Consulting
BioCryst Pharmaceuticals - Consulting
Bionic Vision Technologies - Consulting
Biovisics Medical, Inc - Consulting
Boehringer-Ingelheim Pharma - Consulting
Clearside Biomedical - Consulting
EyePoint Pharmaceuticals - Consulting
Frontera Therapeutics - Consulting
Genentech - Consulting
Glaukos - Consulting
Iveric Bio - Consulting
jCyte - Consulting
Kriya Therapeutics - Consulting
Kyowa Kirin, Inc - Consulting
Lineage Cell - Consulting
LumiThera - Consulting
Nanoscope Therapeutics - Consulting
Neurotech Pharmaceuticals - Consulting
Novartis Ophthalmics - Consulting
Ocugen, Inc - Consulting
Oculis SA - Consulting
Ocuphire Pharma - Consulting
OcuTerra Therapeutics - Consulting
Ocutrx Vision Technologies - Consulting
Opthea - Consulting
Optos - Consulting
Ora Inc - Consulting
Palatin Technologies, Inc. - Consulting
Pfizer - Consulting
Perceive Biotherapeutics - Consulting
Ray Therapeutics - Consulting
Regeneron Pharmaceuticals - Consulting
RegenxBio - Consulting
Rezolute - Consulting
Ripple Therapeutics - Consulting
Samsung Bioepis Co. Ltd. - Consulting
Sanofi - Consulting
Science Branding - Consulting
Smilebiotek Zhuhai Limited - Consulting
Stealth BioTherapeutics - Consulting
Sun Pharmaceuticals - Consulting
Thea - Consulting
Unity Biotech - Consulting
Vanotech Ltd. - Consulting
Visgenx, Inc. - Consulting
Vitranu, Inc. - Consulting
Vitro Biopharma - Consulting
Viva Vision Biotech - Consulting
Allegro - Stock
Top Line Results from ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration
Ciulla, Thomas
Clearside Biomedical - Stock Options, Consulting
Assessment of Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 (Vorolanib Intravitreal Insert) Versus Aflibercept: DAVIO 2 Trial Results
Singer, Michael
- Stock
Inflammasome Therapeutics - Stock
Nanoscope - Stock
Olive - Stock
Aviceda - Stock
Adverum - Consulting, Research
Aerie - Consulting, Research
Alimera - Consulting, Speaking, Research
Allergan - Consulting, Speaking, Research
Apellis - Consulting, Speaking, Research
Bausch & Lomb - Consulting, Speaking
Biogen - Consulting, Speaking
EyePoint - Consulting, Speaking
Genentech - Consulting, Speaking, Research
Iveric Bio - Consulting, Speaking, Research
Novartis - Consulting, Research
Ocular Therapeutix - Consulting, Research
Regeneron - Consulting, Speaking, Research
Unity - Consulting, Research
Stealth - Consulting
Neurotech - Consulting
Coherus - Speaking
Ashvanta - Research
Clearside - Research
Icon - Research
Ionis - Research
Kalvista - Research
Kodiak - Research
Janssen - Research
Ocuterra - Research
Opthea - Research
Optos - Research
Oysterpoint - Research
Recens - Research
Rezolute Medical -
Rezolute Medical - Research
Ribomic - Research
Santen - Research
Senju - Research
Sydnexis - Research
Valo - Research
IMAGING IV AND MACULAR DISEASE
Post Hoc Analysis of Treatment Response in Participants with Smaller Baseline Ellipsoid Zone Area Loss Across Two Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2
Wykoff, Charles
AbbVie, Aerie, Alcon, Ascidian, Bausch + Lomb, Cholgene, IACTA, Kiora, Merck, Ocular Therapeutix, Ocuphire, OcuTerra, ONL, Opthea, Perfuse, Ray, Resonance, Sanofi, Stealth, Surrozen, Sylentis, THEA, Therini - Consulting
4DMT, Adverum, Alimera, Allgenesis, Annexon, Apellis, Aviceda, Bayer, Boehringer Ingelheim, Clearside, Curacle, EyeBiotech, EyePoint, Genentech, Gyroscope, IVERIC Bio, Janssen, Kodiak, Nanoscope, Neurotech, NGM, Novartis, Oxular, Perceive Bio, Regeneron - Consulting, Research
RegenXBio, Roche, Sandoz, Valo - Consulting, Research
Affamed, Alexion, Alkahest, Amgen, Annexin, Chengdu Origen, Gemini, GSK, Ionis, Kyowa Kirin, Pykus, Rezolute, Senju, Shanghai Henlius, Skyline - Research
ONL, Panther, PolyPhotonix, Recens Medical, Vitranu - Stock Options
InGel, TissueGen, Visgenx - Stock Options, Consulting
Outer Foveal Microdefects in Central Serous Chorioretinopathy: Long-term Follow-up
Mrejen, Sarah
Roche - Consulting
Bayer - Consulting
novartis - Consulting
Inversion of asymmetric vortex vein dilatation in pachychoroid spectrum diseases
Matsumoto, Hidetaka
Novartis - Speaking, Advisor
Chugai - Speaking, Advisor
Santen - Speaking
Bayer - Speaking
Senju - Advisor
One-year choroidal thickness changes after photodynamic therapy for central serous chorioretinopathy evaluated by widefield optical coherence tomography
Koizumi, Hideki
- Nothing to Disclose
OCT-Angiography Based Blood Flow Evidence as a Surrogate of Disease Activity in Polypoidal Choroidal Vasculopathy
Lupidi, Marco
Apellis - Advisor
Abbvie - Advisor
Bayer - Advisor
Novartis - Advisor
Roche - Advisor
Clinical Subtypes of Extensive Macular Atrophy with Pseudodrusen-like Appearance
Battaglia Parodi, Maurizio
- Nothing to Disclose
Rheumatic Fever Disease as a Possible Contributor to Extensive Macular Atrophy (EMAP) with Pseudodrusen
Lima, Luiz
- Nothing to Disclose
Predictors of Macular Atrophy secondary to Serous PED Collapse in Eyes with Type 3 Neovascularization and AMD
Borrelli, Enrico
Bayer - Consulting, Speaking
Roche - Consulting, Speaking
Zeiss - Consulting, Speaking
Abbvie - Consulting, Speaking
NEOVASCULAR AMD II
Pivotal Study towards Effectiveness of Artificial Intelligence (AI) based analysis of Home OCT and its Clinical Implications
Loewenstein, Anat
NotalVision - Consulting
Pivotal Study Comparing Home and In-Office OCT Based Visualization and Clinical Implications for Management of Neovacular Age Related Macular Degeneration (nAMD)
Heier, Jeffrey
Notal Vision - Consulting
Clinical Impact of Continuous Drug Delivery With the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Arevalo, J. Fernando
Apellis, Astellas - Advisor
AbbVie, Alimera, Dutch Ophthalmic Research Center, EyePoint, Genentech, Inc. - Consulting
Elsevier, Springer SBM LLC - IP Rights
Topcon - Research
Outcomes of Treat-and-Extend using Aflibercept in Type 3 Macular Neovascularization: A Prospective Clinical Trial
Kim, Jae Hui
Bayer Korea - Consulting, Research
Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: 156-Week Results From the PULSAR Extension
Wong, Tien
Abbvie Pte Ltd - Consulting
Shanghai Henlius - Consulting
Sanofi - Consulting
Roche - Consulting
Quaerite Biopharm Research Ltd - Consulting
Plano - Consulting
Opthea Limited - Consulting
Novartis - Consulting
Aldropika Therapeutics - Consulting
Genentech - Consulting
Iveric Bio - Consulting
Carl Zeiss - Consulting
Boehringer-Ingelheim - Consulting
Bayer - Consulting
Aldropika Therapeutics -
EyRiS - IP Rights, Private
Visre - IP Rights, Private
Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD)
Holekamp, Nancy
F. Hoffmann La Roche Pharmaceuticals - Stock, Employment
Notal Vision - Stock, Stock Options
Early Latin American Experience with Faricimab for Retinal Diseases: FARI-LATAM Study for the Pan-American Collaborative Retina Study (PACORES) Group
Wu, Lihteh
Roche - Consulting, Speaking, Advisor
Bayer - Consulting, Speaking, Advisor
Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naïve nAMD: TENAYA/LUCERNE Post Hoc Analyses
Tan, Colin
Astellas - Speaking, Research
Bayer - Speaking, Research
Roche - Speaking, Research
Faricimab for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung, Gemmy
Roche - Consulting, Speaking, Research, Advisor
Bayer - Consulting, Speaking, Research, Advisor
Novartis - Speaking
Allergan - Consulting
Boehringer Ingelheim - Consulting
Samsung - Consulting
Topcon - Consulting
NON-NV AMD III: GA
Optical Coherence Tomography to Function (OCT Fx) Delphi Study: Global Consensus on Measurement and Analysis of the Ellipsoid Zone in Geographic Atrophy (GA)
Schmidt-Erfurth, Ursula
Apellis, Bayer, Abbvie, Medscape, Allergan, Roche, Boehringer, Aviceda, Annexon, Topcon, Alkeus, Astellas - Consulting
Roche, bayer, abbvie - Speaking
Abbvie, Apellis, Alcon - Other
Genentech, Kodiak, Novartis, REtinsight, Apellis - Research
Progression of Small-Size Geographic Atrophy Secondary to Age-related Macular Degeneration
Yu, Seung-Young
Bayer - Research
Boehringer Ingelheim - Advisor
Carl Zeiss - Consulting, Research, Advisor
Heidelberg - Speaking
iCare - Advisor
Johnson & Johnson - Speaking
Samsung Bio - Advisor
Visual Loss in Geographic Atrophy: Learnings From the Lampalizumab Trials
Ferrara, Daniela
Genentech, Inc - Employment
Roche - Stock, Stock Options
Fellow Eye Analysis in Bilateral GA due to AMD: Long-term Data from the OAKS, DERBY, and GALE Studies
Albini, Thomas
Adverum Biotechnologies - Consulting, Advisor
Apellis Pharmaceuticals - Consulting, Advisor
Applied Genetic Technologies Corp. - Consulting, Advisor
Bausch + Lomb - Consulting, Advisor
Beaver-Visitec International - Consulting, Advisor
Clearside Biomedical - Consulting, Advisor
EyePoint Pharmaceuticals - Consulting, Advisor
Genentech - Consulting, Advisor
Mallinckrodt Pharmaceuticals - Consulting, Advisor
Novartis - Consulting, Advisor
RegenxBio - Consulting, Advisor
Development and Validation of a Time-to-Event Risk Calculator for Patients with Geographic Atrophy (GA) Secondary to AMD
Rachitskaya, Aleksandra
AbbVie/Allergan, Alcon, Apellis Pharmaceuticals, Regeneron, Iveric Bio, Roche/Genentech, Ocular Therapeutix, Samsara, EyePoint, Boehringer Ingelheim, 4D Molecular Therapeutics - Consulting
Samsara - Advisor
Apellis Pharmaceuticals, Iveric Bio, Genentech, Regeneron - Speaking
Beacon Therapeutics, Apellis Pharmaceuticals, DRCR Retina Network, and Roche/Genentech, Regeneron - Research
Real-World Efficacy and Safety of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in AMD
Rosenfeld, Philip
Abbvie - Consulting
Annexon - Consulting
Apellis - Stock, Consulting
Bayer - Consulting
Boehringer-Ingelheim - Consulting
Carl Zeiss Meditec - Consulting, Research
Eyepoint - Consulting
Genentech/Roche - Consulting
Gyroscope - Research
Ocudyne - Stock Options, Consulting
InflammX - Stock Options, Consulting
Regeneron - Consulting
Unity - Consulting
Valitor - Stock Options, Consulting
Long-Term Efficacy and Safety of Pegcetacoplan over 48-Months: Gale Open-Label Extension Study
Singerman, Lawrence
- Nothing to Disclose
ARTIFICIAL INTELLIGENCE I
Comparative AI based on Pairwise Comparisons has the Potential to Overcome Barriers to the Introduction of Artificial Intelligence Systems in Medical Image Diagnosis
Harding, Simon
AI-Sight - Stock, IP Rights
Privacy Preserving Technology using Federated Learning and Blockchain in protecting against Adversarial Attacks for Retinal Imaging
Ting, Daniel
- IP Rights
EyRIS - IP Rights
Specialist vision-language models for clinical ophthalmology
Lotery, Andrew
Apellis - Consulting
Outlook Therapeutics - Consulting
Roche - Consulting
Jannsen - Consulting
Dye-free fluorescein angiography and retinal leakage analysis.
Cruess, Alan
- Nothing to Disclose
AI analysis of OCT images from a Phase 1b study of ONL1204 Fas Inhibition treatment for geographic atrophy secondary to age-related macular degeneration
Kuppermann, Baruch
Allergan, Apellis, Clearside, Genentech Inc, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio - Research
Alkeus, Allegro Ophthalmics, Allergan/AbbVie, Amgen, Apellis, Astellas, Aviceda Therapeutics, Clearside, Coherus, EyeBio, Eyedaptic, EyePoint, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Mobius, Molecular Partners, Novart - Consulting
Allergan, Coherus, Genentech, Roche - Speaking
BASIC SCIENCE AND AI II
Comparison of Geographic Atrophy (GA) Lesion Measurements and Growth Rates Using Semiautomated and Artificial Intelligence (AI) Software
Ambresin, Aude
- Nothing to Disclose
AI-assisted mathematical modeling of geographic atrophy growth
Mandava, Naresh
ONL Therapeutics - Consulting
Alcon corporation - IP Rights
Somalogic Corporation - Consulting
Regeneron Corporation - Research
-
A Data-Driven Natural Language Processing (NLP) Platform for Clinician-Led Exploration of Retinal Fluid Dynamics and Personalized Management of Neovascular Age-Related Macular Degeneration (nAMD)
Zur, Dinah
Bayer - Consulting, Speaking, Advisor
Roche - Consulting, Speaking, Research, Advisor
Abbvie - Consulting, Speaking, Research, Advisor
Taro - Consulting
Janssen&Janssen - Advisor
Mediterranean and high-fat diets alter choroidal neovascularization and distinctly shape gut microbiota and metabolites
Skondra MD,PhD, Dimitra
Abbvie - Consulting
Biogen - Consulting
Iveric Bio - Consulting
Eyepoint - Consulting
Regeneron - Speaking
MedSpoke - Consulting
Lumina - Consulting
trinity partners - Consulting
Trinity life science - Consulting
keywest health - Consulting
Modulation of Intravitreal Gene Therapy Associated Uveitis (GTAU) with Systemic Immune Modulation in Mice
Pepple, Kathryn
- Consulting
Janssen Research & Development - Consulting
Astellas Pharma - Consulting
Adverum - Consulting
Roche/Genentech - Consulting
Ultra-local Retinal Immunosuppressive Nanoparticles to Mitigate Graft Rejection in Retinal Cell Therapy
Singh, Mandeep
Bayer - Consulting, Research
Novartis - Consulting
Johnson & Johnson - Consulting
Opus Therapeutics - Consulting
Revision Therapeutics - Consulting
Agnos Therapeutics - Stock Options, IP Rights
Biodegradable Microneedle Arrays as a Novel Ocular Drug Delivery System
Kang-Mieler, Jennifer
- Nothing to Disclose
UVEITIS
Cytomegalovirus Anterior Uveitis: A Multicenter Study in Taiwan
Hwang, Yih-Shiou
- Nothing to Disclose
Acute Retinal Necrosis: Morphological changes of the macula
Akiyama, Hideo
- Nothing to Disclose
Fern-Like Retinal Vasculopathy in Intermediate Uveitis
Cicinelli, Maria Vittoria
- Nothing to Disclose
The AIRE retinopathy Spectrum
Pulido, Jose
- Nothing to Disclose
Nonparaneoplastic Autoimmune Retinopathy: Scoping Review and Suggested Reporting Guidelines
Jain, Nieraj
SpliceBio Inc - Research
Ocugen Inc - Research
Janssen Pharmaceuticals Inc - Research
36-month Effectiveness, Safety, and Intraocular Pressure Intervention Data From a Real-world Registry (CALM Registry) of the Fluocinolone Acetonide 0.18 mg Implant in Patients With Chronic Noninfectious Uveitis Affecting the Posterior Segment
Kurup, Shree
Santen - Consulting
Regeneron - Research
Genentech - Research
Proviant - Research
Durability and safety of suprachoroidal triamcinolone acetonide injectable suspension for uveitic macular edema in real-world clinical practice.
Emami, Parisa
Bausch and Lomb - Consulting
Abbvie - Consulting
Regeneron - Research
Eyepoint - Consulting
Interleukin-6 Inhibition with Vamikibart in Patients with Uveitic Macular Edema: DOVETAIL, MEERKAT, and SANDCAT Trials
Holekamp, Nancy
F. Hoffmann La Roche Pharmaceuticals - Stock, Employment
Notal Vision - Stock, Stock Options
IMAGING V AND MACULAR DISEASE
Comparison of Two-Color (RG) and Three-Color (RGB) Images obtained by Ultra-WideField Fundus Imaging (Optos)
Kondo, Mineo
-
Alcon - Research
Santen - Research, Other
Senjyu - Research, Other
Chugai - Research, Other
Asahi-Kasei - Research, Other
Novartis - Other
Bayer - Other
Nikon - Other
In Vivo Assessment of Peripheral Vitreous with Ultra-Widefield Swept-Source Optical Coherence Tomography in Rhegmatogenous Retinal Detachment.
Muni, Rajeev
Alcon, Apellis, AbbVie, Bayer, Bausch Health, Roche - Consulting
Pathogenesis of Ectopic Inner Foveal Layers (EIFL) and Its Impact on Visual Recovery after Epiretinal Membrane Peeling
Sarraf, David
Amgen - Research
Amgen - Consulting, Research
Annexon - Consulting
Avecida - Consulting
Boehringer - Consulting, Research
Novartis - Consulting
iCare/Eidon - Research
Visionix/Optovue - Consulting, Research
Ocuphire - Consulting
Peripapillary Retinoschisis- The Expanded Spectrum and New Insights from Multi-Modal Imaging
Fung, Adrian
Alcon - Consulting, Speaking, Research, Advisor
Bayer - Consulting, Speaking, Research, Advisor
Roche - Consulting, Speaking, Research, Advisor
Novartis - Consulting, Speaking
Apellis - Advisor
Astellas - Advisor
Abbvie - Speaking, Advisor
Ionis - Research
Opthea - Stock
Retinal Artery Occlusion in Young Patients Without Typical Cardiovascular Risk Factors: Etiologies, Prognosis, and Suggested Work-Up
Miller, Jason
- Nothing to Disclose
Five year treatment outcomes of macular oedema secondary to CRVO in routine clinical practice: The Fight Retinal Blindness! Registry
Barthelmes, Daniel
Bayer - Consulting, Research
Novartis - Research
INHERITED RETINAL DYSTROPHY II
Functional Transition Points: Assessing Changes in Visual Field Sensitivity with Function-guided Prespecification of Points
Huckfeldt, Rachel
AGTC - Research
Biogen - Research
-
Janssen - Consulting, Research
MeiraGTx - Research
SpliceBio - Consulting, Research
BlueRock Therapeutics - Consulting
Saliogen - Consulting
Sanofi - Consulting
Sepul Bio (Thea) - Consulting
Sunovion - Consulting
Application of new molecular technologies in the genetic diagnosis of hereditary retinal dystrophies.
Arias, Luis
Alcon - Advisor
BVI - Advisor
Bayer - Advisor
Roche - Advisor
Thea - Advisor
Topcon - Speaking
Primary Outcome Results from the Moran AMD Genetic Testing Assessment (MAGENTA) Trial
Bernstein, Paul
Heidelberg Engineering - Research
Kemin Health - Consulting, Speaking, Research
DSM - Speaking
Omniactives - Speaking
Co-Localization of RPE Loss and Increased Choroidal Vascular Lumen Volume
Iezzi, Raymond
-
Johnson and Johnson Pharmaceutical - Consulting
Peripheral Retinal Vascular Loss in Retinitis Pigmentosa
Ameri, Hossein
Beyang Therapeutics - Consulting
Eye Kleur - Advisor
Gene Editing for CEP290-Associated Retinal Degeneration
Aleman, Tomas
University of Pennsylvania - IP Rights
Editas Medicine, Inc - Research
Opus Genetics - Research
Atsena Therapeutics - Research
Spark Therapeutics - Research
BASIC SCIENCE AND IRD III
Clinical Evidence of a Photoreceptor Origin in Diabetic Retinal Disease
Rajagopal, Rithwick
- Nothing to Disclose
The ERG i-wave Associates with a Myopia Risk Locus Supporting Relevance of Retinal OFF-pathways in Myopia
Mahroo, Omar
Janssen - Advisor
Human umbilical cord lining epithelial cells as a hypoimmunogenic source for retinal regenerative therapy
Su, Xinyi
- Nothing to Disclose
Translational Models for Choroidal Endothelial Cell Injury and Therapeutic Replacement Using Self-Healing Hydrogels
Han, Ian
- Nothing to Disclose
Matrix Metalloproteinase 2 and Choroidal Atrophy in Choroideremia
Fahim, Abigail
Janssen - Consulting
Monocarboxylate transporter (MCT) 4 inhibition ameliorates key aspects of PVR pathogenesis in vitro and is non-toxic to RPE cell viability and retinal function
Kuriyan, Ajay
Recens medical - Stock Options, Consulting
Alimera Sciences - Consulting
Allergan - Consulting
Astellas - Consulting
Bausch + Lomb - Consulting
Eyepoint Pharmaceuticals - Consulting
Genentech/Roche - Consulting, Speaking, Research
4DMT - Research
Adverum - Research
Annexon - Research
Alcon Laboratories - Research
Lifenet Health, - Consulting
Topotecan as a Therapy for Proliferative Vitreoretinopathy: Insights from a Patient-Derived Cell Model
Kim, Leo
- Research
CureVac - Research
Ingenia Therapeutics - Stock, Stock Options, Advisor
Pykus Therapeutics - Stock, Advisor
Evangelos S. Gragoudas Award
Liquid biopsy for proliferative diabetic retinopathy: human vitreous single-cell transcriptomics reveals inflammatory T cell signature
Haliyur, Rachana
- Nothing to Disclose
VITREORETINAL SURGERY AND PHARMACOTHERAPY
Trends in Medicare reimbursement and service volume of vitreoretinal procedures over two decades
Adelman, Ron
Janssen - Consulting
Identifeye - Consulting
Pre- and Post- Operative Light Scattering Characteristics (LSC) of Symptomatic Vitreous Floaters and Opacities (VFO)
Stanga, Paulo-Eduardo
Intalight (San Jose, California, USA) - Consulting
Optos (Dunfermline, UK): - Consulting
Association between systemic methotrexate therapy and proliferative vitreoretinopathy
Stewart, Jay
Carl Zeiss Meditec - Consulting
Merck - Consulting
Valitor - Stock Options, Consulting
Long Bridge - Stock, Consulting
Twenty Twenty - Consulting
Oculgen - Consulting
1-step vs. 2-step subretinal injection trial (1,2-SIT) – a randomized controlled trial to compare two methods of sub-retinal injection
Simunovic, Matthew
- Nothing to Disclose
Dynamic Closure Techniques for Treatment of Full Thickness Macular Hole without Gas Tamponade
Zhao, Peiquan
- Nothing to Disclose
Finesse-loop Giant Retinal Flap as Primary Surgery for Idiopathic Macular Hole
Jorge, Rodrigo
- Nothing to Disclose
Incidence of Anti-Vascular Endothelial Growth Factor Intravitreal Injections for Non-Food and Drug Administration Approved Indications
Friedman, Scott
H. Dunbar Hoskins, Jr MD Center for Quality Eye Care IRIS® Registry Research Fund - Other
Amgen - Research, Advisor
Chengdu Kanghong - Research
Bayer - Research
Clearside Biomed - Research
Eyepoint - Research
Genentech - Research, Advisor
Kodiak Science - Research
Ocular Therapeutix - Research, Advisor
Opthea - Research
Regenexbio - Research
Regeneron - Research
Boehringer Ingelheim - Research
Graybug Vision - Research
-
Comparison of Silicone Oil Droplet Quantity from Syringes Used for Intravitreal Injections
Thompson, John
Genentech - Research
Cognition Therapeutics - Research
Alexion Pharmaceuticals - Research
Implementation of Optimized Surgical Steps for the Port Delivery System With Ranibizumab (PDS) and the Incidence of Endophthalmitis and Associated Patient Outcomes
Chaudhry, Nauman
Alexion, Apellis, Aviceda, Bayer, Boehringer Ingelheim, EyeBio, EyePoint, Genentech, Inc./Roche, Kodiak Sciences, Ocular Therapeutix, Oculis, Outlook, Regeneron, Spectrum - Research
PEDIATRICS
Evaluating the Utility of Initial Exams in Retinopathy of Prematurity: Proposal of FIRST-ROP Algorithm for a Medium-Risk Cohort
Patel, Nimesh
- Advisor
Alcon, Dorc, Alimeria, EyePoint, Genentech, Regeneron, Kyoto Drug Company, Apellis - Advisor
Pediatric Patients With Posterior Segment Findings Identified From a Large School Screening Program
Schwartz, Stephen
GE Healthcare Technologies Inc. - Stock
Genotypic Spectrum, Phenotypic Variability and Clinical Correlations in Familial Exudative Vitreoretinopathy: Insights from a Single-Center Cohort
Hartnett, Mary Elizabeth
- IP Rights
- Consulting, Research, Advisor, Exec Board
- Consulting, Speaking, Research, Advisor
Johnson and Johnson - Consulting
NEI/NIH - Research
Ray therapeutics - Advisor
Jack McGovern coats Disease Foundation - Exec Board
Faricimab for Coats Disease
Yonekawa, Yoshihiro
Alcon - Consulting
Bausch+Lomb - Consulting
Genentech/Roche - Consulting, Research
Pykus - Consulting
Versant Health - Advisor
Kyowa Kirin - Research
Ocugen - Research
Regeneron/Bayer - Research
DIABETIC RETINOPATHY III
Diabetic Peripheral Neuropathy
Brown, Gary
Center for Value-Based Medicine - health economics research - Consulting, Private
The Risk of Hypoglycemia in Diabetes: An Outcomes-Based Analysis
Kurup, Shree
Santen - Consulting
Regeneron - Research
Genentech - Research
Proviant - Research
20 Year Trends in Diabetic Retinal Disease
VanderBeek, Brian
EyePoint Pharmaceuticals - Consulting
Using a Diagnostic Dataset to Enrich Recruitment for DRCR Retina Network Clinical Trials: A Feasibility Study
Brucker, Alexander
- Nothing to Disclose
The INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy (INSPIRE): Baseline and 1-Year Results
Kim, Stephen
- Nothing to Disclose
Retinal Fluid and Thickness Fluctuations in Pagoda Trial of Port Delivery System With Ranibizumab (PDS) in Patients With Diabetic Macular Edema (DME)
Tan, Gavin
AbbVie, Alcon, Bayer, Eyris, Leica, Novartis, Optos-Nikon, Roche, ZEISS - Consulting
Santen - Research
Long-term Effects of Anti-VEGF Therapy versus Panretinal Photocoagulation on Retinal Vessel Caliber in Eyes with Proliferative Diabetic Retinopathy
Sun, Jennifer
Optovue - Research
Boehringer Ingelheim - Research
Novo Nordisk - Research
Genentech/Roche - Research
Physical Sciences, Inc - Research
Boston Micromachines - Research
Week 96 Outcomes in Aflibercept 8 mg- and 2 mg-Treated Patients by Prior DME Treatment Status: a Subgroup Analysis of the Phase 2/3 PHOTON Trial
Williams, Basil
AbbVie - Consulting
Alcon - Consulting
Alimera Sciences - Consulting
Astellas Pharma - Consulting
Castle Biosciences - Consulting
DORC - Consulting
EyePoint Pharmaceuticals - Consulting
Genentech - Consulting
Immunocore - Consulting
Regeneron Pharmaceuticals, Inc. - Consulting
Lumata Health - Stock Options
NV AMD III
Clinical Characteristics and Treatment Outcomes of Breakthrough Vitreous Hemorrhage in Peripheral Exudative Hemorrhagic Chorioretinopathy (PEHCR)
Mieler, William
- Nothing to Disclose
Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration
Starr, Matthew
Abbvie - Consulting
Gyroscope Therapeutics - Consulting
Alimera Sciences - Consulting
Evolve Medical - Speaking
Changes in PED associated with MMP9 genotype in treated eyes with neovascular AMD
Sohn, Elliott
- Nothing to Disclose
Macular Atrophy (cRORA) during long-term anti-VEGF therapy in nAMD – characteristics and functional implications
Pauleikhoff, Daniel
Novartis - Advisor
Roche - Advisor
Bayer - Advisor
Apellis - Advisor
Astellas - Advisor
Heidelberg Engineering - Advisor
Associations between macular fibrosis and macular atrophy in patients with neovascular aged macular degeneration.
Chakravarthy, Usha
Aviceda - Consulting
Annexon - Consulting, Advisor
Apellis - Consulting, Advisor
Eyepoint - Consulting, Advisor
Ocular TherapeutIX - Consulting
Hoffman La Roche - Consulting
Unity - Consulting, Advisor
Boehringer Ingelheim - Research
Awards:Daniel F. Martin, MDBy-Laws:Anita Agarwal, MDCredentials:Manjot K. Gill, MDEndowment Committee:Daniel F. Martin, MD
Meeting Planning:William F. Mieler, MD, FACS, FARVONominating:Ivana K. Kim, MDProgram:David Sarraf, MDResearch:Amani Fawzi, MDWebsite:Dilraj S. Grewal, MDInternational Membership:Gemmy Cheung, MDYoung Member Representative:Katherine E. Talcott, MDAAO Representative:Sunir J. Garg, MD, FACS
Mark W. Johnson, MD
Glenn J. Jaffe, MD
Daniel F. Martin, MD
Immediate Past President
SriniVas R. Sadda, MD